Brain proton magnetic resonance spectroscopy and neuromuscular pathology in a patient with GM1 gangliosidosis

Journal of Child Neurology

Volumn 23, Issue 1, 2008, Pages 73-78

  Brunetti Pierri, Nicola ^a   Bhattacharjee, Meenakshi B ^a   Wang, Zhiyue J ^a   Chu, Zili ^a   Wenger, David A ^b   Potocki, Lorraine ^a,c   Hunter, Jill ^a   Scaglia, Fernando ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

galactosidase; GLB1; GM1 gangliosidosis; Proton magnetic resonance spectroscopy

Indexed keywords

BETA GALACTOSIDASE;

ARTICLE; BRACHYCEPHALY; CASE REPORT; CLINICAL FEATURE; DEVELOPMENTAL DISORDER; ELECTROENCEPHALOGRAM; FEMALE; GM1 GANGLIOSIDOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; MUSCLE HYPOTONIA; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROMUSCULAR DISEASE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ASPARTIC ACID; AXONS; BIOLOGICAL MARKERS; BRAIN; FEMALE; GANGLIOSIDOSIS, GM1; GLIOSIS; HUMANS; INFANT; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MICROCIRCULATION; MUSCLE, SMOOTH, VASCULAR; NERVE DEGENERATION; NERVE FIBERS, MYELINATED; NEUROGLIA; OLIGOSACCHARIDES; PREDICTIVE VALUE OF TESTS; SCHWANN CELLS; SENSITIVITY AND SPECIFICITY;

EID: 37449017751     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073807307088     Document Type: Article

References (42)

1. Okada S., O'Brien JS Generalized gangliosidosis: Beta-galactosidase deficiency. Science. 1968;160(831):1002-1004.
2. O'Brien JS, Stern MB, Landing BH, O'Brien JK, Donnell GN Generalized gangliosidosis: Another inborn error of ganglioside metabolism? Am J Dis Child. 1965;109:338-346.
3. Zimmerman RA, Wang ZJ The value of proton MR spectroscopy in pediatric metabolic brain disease. AJNR Am J Neuroradiol. 1997;18(10):1872-1879.
4. Kuker W., Ruff J., Gaertner S., et al. Modern MRI tools for the characterization of acute demyelinating lesions: Value of chemical shift and diffusion-weighted imaging. Neuroradiology. 2004;46(6):421-426.
5. Wenger DA, Tarby TJ, Wharton C. Macular cherry-red spots and myoclonus with dementia: Coexistent neuraminidase and beta-galactosidase deficiencies. Biochem Biophys Res Commun. 1978;82(2):589-595.
6. Provencher SW Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30(6):672-679.
7. Georgiou T., Drousiotou A., Campos Y., et al. Four novel mutations in patients from the Middle East with the infantile form of GM1-gangliosidosis. Hum Mutat. 2004;24(4):352.
8. Michalski JC, Lemoine J., Wieruszeski JM, et al. Characterization of a novel type of chain-terminator Gal beta 1-6Gal beta 1-4)GlcNAc in an oligosaccharide related to N-glycosylated protein glycans isolated from GM1 the urine of patients with gangliosidosis. Eur J Biochem. 1991;198(2):521-526.
9. Chiu NC, Qian WH, Shanske AL, et al. A common mutation site in the beta-galactosidase gene originates in Puerto Rico. Pediatr Neurol. 1996;14(1):53-56.
10. Gururaj A., Sztriha L., Hertecant J., et al. Magnetic resonance imaging findings and novel mutations in GM1 gangliosidosis. J Child Neurol. 2005;20(1):57-60.
11. Gascon GG, Ozand PT, Erwin RE GM1 gangliosidosis type 2 in two siblings. J Child Neurol. 1992;7(suppl):S41-S50.
12. van der Voorn JP, Pouwels PJ, Kamphorst W., et al. Histopathologic correlates of radial stripes on MR images in lysosomal storage disorders. AJNR Am J Neuroradiol. 2005;26(3):442-446.
13. Di Rocco M, Rossi A., Parenti G., et al. Different molecular mechanisms leading to white matter hypomyelination in infantile onset lysosomal disorders. Neuropediatrics. 2005;36(4):265-269.
14. Erol I., Alehan F., Ali Pourbagher M., et al. Neuroimaging findings in infantile GM1 gangliosidosis. Eur J Paediatr Neurol. 2006;10(5-6):245-248.
15. Mathews PM, Andermann F., Silver K., et al. Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. Neurology. 1993;43(12):2484-2490.
16. Barkovich AJ, Good WV, Koch TK, et al. Mitochondrial disorders: Analysis of their clinical and imaging characteristics. AJNR Am J Neuroradiol. 1993;14(5):1119-1137.
17. Kruse B., Hanefeld F., Christen HJ, et al. Alterations of brain metabolites in metachromatic leukodystrophy as detected by localized proton magnetic resonance spectroscopy in vivo. J Neurol. 1993;241(2):68-74.
18. Sylvain M., Arnold DL, Scriver CR, et al. Magnetic resonance spectroscopy in Niemann-Pick disease type C: Correlation with diagnosis and clinical response to cholestyramine and lovastatin. Pediatr Neurol. 1994;10(3):228-232.
19. Grodd W., Krageloh-Mann I., Klose U., et al. Metabolic and destructive brain disorders in children: Findings with localized proton MR spectroscopy. Radiology. 1991;181(1):173-181.
20. Brockmann K., Dechent P., Wilken B., et al. Proton MRS profile of cerebral metabolic abnormalities in Krabbe disease. Neurology. 2003;60(5):819-825.
21. Arnold DL, Matthews PM, Francis G., et al. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: Assessment of the load of disease. Magn Reson Med. 1990;14(1):154-159.
22. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain. 1994;117(pt1):49-58.
23. De Stefano N., Matthews PM, Antel JP, et al. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol. 1995;38(6):901-909.
24. Bruhn H., Frahm J., Merboldt KD, et al. Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. Ann Neurol. 1992;32(2):140-150.
25. Koopmans RA, Li DK, Zhu G., et al. Magnetic resonance spectroscopy of multiple sclerosis: In-vivo detection of myelin breakdown products. Lancet. 1993;341(8845):631-632.
26. Fisher SK, Novak JE, Agranoff BW Inositol and higher inositol phosphates in neural tissues: Homeostasis, metabolism and functional significance. J Neurochem. 2002;82(4):736-754.
27. Kasperzyk JL, d'Azzo A., Platt FM, et al. Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice. J Lipid Res. 2005;46(4):744-751.
28. Matsuda J., Suzuki O., Oshima A., et al. Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. Proc Natl Acad Sci U S A. 2003;100(26):15912-15917.
29. Folkerth RD Abnormalities of developing white matter in lysosomal storage diseases. J Neuropathol Exp Neurol. 1999;58(9):887-902.
30. Murnane RD, Wright RW Jr, Ahern-Rindell AJ, et al. Prenatal lesions in an ovine fetus with GM1 gangliosidosis. Am J Med Genet. 1991;39(1):106-111.
31. Kaye EM, Alroy J., Raghavan SS, et al. Dysmyelinogenesis in animal model of GM1 gangliosidosis. Pediatr Neurol. 1992;8(4):255-261.
32. van der Voorn JP, Kamphorst W., van der Knaap MS, et al. The leukoencephalopathy of infantile GM1 gangliosidosis: Oligodendrocytic loss and axonal dysfunction. Acta Neuropathol (Berl). 2004;107(6):539-545.
33. Folkerth RD, Alroy J., Bhan I., et al. Infantile G(M1) gangliosidosis: complete morphology and histochemistry of two autopsy cases, with particular reference to delayed central nervous system myelination. Pediatr Dev Pathol. 2000;3(1):73-86.
34. Tome FM, Fardeau M. Ultrastructural study of a muscle biopsy in a case of GM1 gangliosidosis type I. Pathol Eur. 1976;11(1):15-25.
35. Dayan AD, Graveson GS, Robinson PK, et al. Globular neuropathy: A disorder of axons and Schwann cells. J Neurol Neurosurg Psychiatry. 1968;31(6):552-560.
36. Vallet JM, Gil R., Leboutet MJ, Hugon J., Moulies D. Congenital hypo- and hypermyelination neuropathy. Acta Neuropathol (Berl). 1987;74(2):197-201.
37. Ohnishi A., Murai Y., Ikeda M., et al. Autosomal recessive motor and sensory neuropathy with excessive myelin outfolding. Muscle Nerve. 1989;12(7):568-575.
38. Gabreels-Festen AA, Joosten EM, Gabreels FJ, et al. Congenital demyelinating motor and sensory neuropathy with focally folded myelin sheaths. Brain. 1990;113(pt6):1629-1643.
39. Umehara F., Takenaga S., Nakagawa M., et al. Dominantly inherited motor and sensory neuropathy with excessive myelin folding complex. Acta Neuropathol (Berl). 1993;86(6):602-608.
40. Dupree JL, Coetzee T., Suzuki K., et al. Myelin abnormalities in mice deficient in galactocerebroside and sulfatide. J Neurocytol. 1998;27(9):649-659.
41. Bosio A., Bussow H., Adam J., et al. Galactosphingolipids and axono-glial interaction in myelin of the central nervous system. Cell Tissue Res. 1998;292(2):199-210.
42. Vyas AA, Patel HV, Fromholt SE, et al. Gangliosides are functional nerve cell ligands for myelin-associated glycoprotein (MAG), an inhibitor of nerve regeneration. Proc Natl Acad Sci U S A. 2002;99(12):8412-8417.